PTC Therapeutics (NASDAQ:PTCT) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET
Company Participants
Kylie O'Keefe - Senior Vice President, Head of Global Commercial & Corporate Strategy
Stuart Peltz - Chief Executive Officer
Matthew Klein - Chief Operating Officer
Eric Pauwels - Chief Business Officer
Emily Hill - Chief Financial Officer
Conference Call Participants
Eric Joseph - JPMorgan
Raju Prasad - William Blair
Kristen Kluska - Cantor Fitzgerald
Joe Thome - Cowen & Company
Tazeen Ahmad - Bank of America
Alex Xenakis - Truist Securities
Stephen Mallon - RBC Capital
Alexander Nackenoff - Raymond James
Operator
Good day and thank you for standing by. Welcome to the PTC Second Quarter 2022 Financial Results and Corporate Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Kylie O'Keefe, Senior Vice President, Head of Global Commercial and Corporate Strategy. Please go ahead.
Kylie O'Keefe
Good afternoon and thank you for joining us today to discuss the PTC Therapeutics second quarter 2022 corporate update and financial results. I'm joined today by our Chief Executive Officer, Stuart Peltz; our Chief Operating Officer, Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Emily Hill.
Today's call will include forward-looking statements based on our current expectations. Please take a moment to review the slide posted on our Investor Relations website in conjunction with the call which contains our forward-looking statements. Our actual results could materially differ from these forward-looking statements, as such statements are subject to risks that can materially and adversely affect our business and results of operation. For a detailed description of applicable risks and uncertainties, we encourage you to review the company's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well as the company's other SEC filings.
We will disclose certain non-GAAP information during this call. Information regarding our use of GAAP to non-GAAP financial measures and a reconciliation of GAAP to non-GAAP is available in today's earnings release.
With that, let me pass the call over to our CEO, Stuart Peltz. Stu?
Stuart Peltz
Thanks, Kylie and good afternoon, everyone and thanks for joining us today. I'm excited to share PTC's second quarter results for what I expect to be a transformational year for the company. Our mission at PTC is to discover and develop innovative therapies and bring them to patients with rare disorders and, in doing so, to create significant value for all of our stakeholders.